Early detection of anthracycline cardiotoxicity in a rabbit model: left ventricle filling pattern versus troponin T determination.
Anthracycline cardiotoxicity represents a serious risk of anticancer chemotherapy. The aim of the present pilot study was to compare the potential of both the left ventricular (LV) filling pattern evaluation and cardiac troponin T (cTnT) plasma levels determination for the early detection of daunorubicin-induced cardiotoxicity in rabbits. The echocardiographic measurements of transmitral LV inflow as well as cTnT determinations were performed weekly for 10 weeks in daunorubicin (3 mg/kg weekly) and control groups (n=5, each). Surprisingly, no significant changes in LV-filling pattern were observed through the study, most likely due to the xylazine-containing anesthesia, necessary for appropriate resolving of the E and A waves. In contrast to the echographic measurement, the dP/dt(min) index obtained invasively at the end of the study revealed a significant impairment in LV relaxation, which was further supported by observed disturbances in myocardial collagen content and calcium homeostasis. However, at the same time cTnT plasma levels were progressively rising in the daunorubicin-treated animals from the fifth week (0.024+/-0.008 microg/l) until the end of the experiment (0.186+/-0.055 microg/l). Therefore, in contrast to complicated non-invasive evaluation of diastolic function, cTnT is shown to be an early and sensitive marker of anthracycline-induced cardiotoxicity in the rabbit model.
Sterba
M
M
Charles University in Prague, Faculty of Medicine in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic. sterbam@lfhk.cuni.cz
Simůnek
T
T
Popelová
O
O
Potácová
A
A
Adamcová
M
M
Mazurová
Y
Y
Holecková
M
M
Gersl
V
V
D000777:Anesthetics / Q000008:administration & dosage; D000818:Animals; D000903:Antibiotics, Antineoplastic; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D002118:Calcium / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D003630:Daunorubicin; D004195:Disease Models, Animal; D015150:Echocardiography, Doppler; D006331:Heart Diseases / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D006339:Heart Rate; D008297:Male; D009200:Myocardial Contraction; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D010865:Pilot Projects; D011817:Rabbits; D013997:Time Factors; D020107:Troponin T / Q000097:blood*; D016277:Ventricular Function, Left; D017725:Ventricular Pressure; D014991:Xylazine / Q000008:administration & dosage
D000777:Anesthetics; D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D020107:Troponin T; D014991:Xylazine; D003094:Collagen; D002118:Calcium; D003630:Daunorubicin